Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
Category: #health  By Saipriya Iyer  Date: 2019-11-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

Triple Gene releases Phase 1 study data for INXN-4001 in heart failure

Triple Gene LLC- a U.S. based cardiovascular gene therapy enterprise recently furnished preliminary data from its Phase 1 trial of INXN-4001, an investigational therapeutic candidate used in the treatment of cardiac failure.

The results were presented on November 7, 2019, at the American Heart Association Annual Meeting. Triple Gene is owned is a majorly owned subsidiary of Intrexon Corporation.

According to Thomas D. Reed, Co-founder and Managing Director at Triple Gene, the data proposes that the combination of the company’s newly developed non-integrating naked plasmid DNA with focused cardiac delivery supported by Retrograde Coronary Sinus Infusion carries the ability to open a new biologics treatment model. It could be used for the treatment of cardiovascular diseases, he further added.

Triple Gene’s Co-founder and Clinical Director, Amit N. Patel, MD, MS, was reportedly quoted stating that 12 patients in the clinical trial have received the drug dosage between the two clinical sites at the University of Arizona, Tucson and The Christ Hospital, Cincinnati. Presently, the company is exploring clinical study designs that consider repetitive dosing along with additional orphan-like heart failure subtypes.

For the record, the investigational therapy by Triple Gene utilizes the non-viral delivery mechanism of a controlled multigenic plasmid developed to express human S100A1, VEGF165 and SDF-1a gene products that may affect progenitor cell recruitment, calcium handling, and angiogenesis. It also targets the fundamental  mechanisms associated with pathological myocardial remodeling. Further, the plasmid treatment is rendered through RCSI, which facilitates cardiac-specific delivery to the heart’s ventricle.

About Triple-Gene

Triple Gene primarily focuses on developing controllable, targeted and multigenic gene therapies to diagnose cardiovascular diseases. The company’s main product is a non-viral clinical gene therapy candidate that drives expression of three candidate genes which are effectively associated with heart failure. 

 

 

Source Credits: https://3gtx.com/wp-content/uploads/2019/11/Triple-Gene_Presented_Preliminary_Phase_1_Trial_Data_at_AHA_Annual_Meeting.pdf



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Vela Diagnostics gains EUA for ViroKey™ SARS-CoV-2 RT-PCR test v2.0
Vela Diagnostics gains EUA for ViroKey™ SARS-CoV-2 RT-PCR test v2.0
By Saipriya Iyer

Vela Diagnostics has recently announced that the U.S. FDA has granted an EUA (Emergency Use Authorization) for its ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 in the United States. This automated p...

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...